---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-276000"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:19:13.592767+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma reports Q3 2025 net loss of $21.1M; highlights 34% ORR with rezatapopt in PYNNACLE study

## Summary
- Cash, cash equivalents, and marketable securities of $129.3M as of Sept 30, 2025; cash runway to end of Q1 2027.
- Overall response rate of 34% (35/103 patients) in Phase 2 PYNNACLE study; 46% ORR in ovarian cancer cohort with median duration of response of 8.0 months.
- Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned for Q1 2027.
- Net loss for Q3 2025 was $21.1M vs $19.2M in Q3 2024, driven by increased R&D costs of $18.2M.
- R&D expenses increased to $18.2M from $16.9M due to advancement of rezatapopt program; G&A decreased to $4.3M from $4.9M.

## SEC filing metadata
- accession: 0001193125-25-276000
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000119312525276000/0001193125-25-276000-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000119312525276000/pmvp-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-276000
- JSON: https://secwatch.observer/filing/0001193125-25-276000.json
- Plain text: https://secwatch.observer/filing/0001193125-25-276000.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.